Treatment with bulevirtide in HIV-infected patients with chronic hepatitis D: ANRS HD EP01 BuleDelta and compassionate cohort.

Date publication

août 2024

Journal

JHEP reports : innovation in hepatology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MINELLO Anne

Tous les auteurs :
de Lédinghen V, Fougerou-Leurent C, Le Pabic E, Pol S, Alfaiate D, Lacombe K, Hilleret MN, Lascoux-Combe C, Minello A, Billaud E, Rosa I, Gervais A, Ratziu V, Ganne N, Pageaux GP, Leroy V, Loustaud-Ratti V, Mathurin P, Chas J, Jezequel C, Métivier S, Dumortier J, Arpurt JP, Asselah T, Roche B, Le Gruyer A, Valantin MA, Scholtès C, Gordien E, Tual C, Kortebi A, Coulibaly F, Rosenthal E, Subic-Levrero M, Roulot D, Zoulim F,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39045338

Résumé

In France, bulevirtide (BLV) became available in September 2019 through an early access program to treat patients with HDV. The aim of this analysis was to evaluate the efficacy and safety of BLV in patients with HIV and HDV coinfection.

Mots clés

Cirrhosis, Entry inhibitors, HBV, HBV DNA, HDV, HDV RNA, HIV, HIV RNA, Hepatitis D, Pegylated interferon

Référence

JHEP Rep. 2024 08;6(8):101057